laroprovstat
Sponsor Astrazeneca PLC · listed as AZN
laroprovstat is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Jan 4, 2027 (day precision, medium confidence), tied to trial NCT07000136. That trial is in Phase 3 and currently active not recruiting, studying Heterozygous Familial Hypercholesterolaemia. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for laroprovstat
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-01-04 | READOUT | medium | NCT07000136 |
| 2027-01-11 | READOUT | medium | NCT07000123 |
Trials for laroprovstat in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06834932 | Phase 2/3 | Active, not recruiting | 2025-07-03 | Experimental | AstraZeneca | Dyslipidaemia |
| NCT07000136 catalyst | Phase 3 | Active, not recruiting | 2027-01-04 | Experimental | AstraZeneca | Heterozygous Familial Hypercholesterolaemia |
| NCT07000123 catalyst | Phase 3 | Active, not recruiting | 2027-01-11 | Experimental | AstraZeneca | Cardiovascular Disease |
| NCT07619131 | Phase 3 | Recruiting | 2027-07-30 | Active comparator | AstraZeneca | Hypercholesterolaemia |
| NCT07000357 | Phase 3 | Recruiting | 2029-10-26 | Experimental | AstraZeneca | Cardiovascular Disease |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts